They are the masters of giving just enough informa
Post# of 590
(Total Views: 255)
Posted On: 06/07/2023 9:37:28 AM
They are the masters of giving just enough information, stated in a way to cover their backs and leave another little ray of hope to keep investors, and potential investors, eagerly anticipating the NEXT big PR.
For years the NEXT PR will be the big one.
Well, the formula is wearing thin and it has been reflected in the steady decline in pps since Thom’s arrival.
Will the NEXT PR be the big one? Or will we get just enough information to wait for the The one to follow.
June 2020 most thought COVID was the sole reason that Hemostyp wasn’t already approved. Eagerly awaiting next PR.
June 2021 most (that misread PRs) eagerly awaiting imminent approval in NEXT PR.
June 2022 all eagerly waiting for the July 2022 FDA meeting and the PR to follow.
June 2023 all eagerly await the latest product test results and the PR to follow.
So in 4 Junes(and much further back, but I made my point) Hemostyp has gone from Imminent approval, to FDA reset, and incredibly, to testing product for specs validity.
Like the $PPS this PMA is going in the wrong direction.
It reminds me of that movie:
The Curious Case of Benjamin Button.
However, if the goal was 30 months of buying opportunities then well done!
For years the NEXT PR will be the big one.
Well, the formula is wearing thin and it has been reflected in the steady decline in pps since Thom’s arrival.
Will the NEXT PR be the big one? Or will we get just enough information to wait for the The one to follow.
June 2020 most thought COVID was the sole reason that Hemostyp wasn’t already approved. Eagerly awaiting next PR.
June 2021 most (that misread PRs) eagerly awaiting imminent approval in NEXT PR.
June 2022 all eagerly waiting for the July 2022 FDA meeting and the PR to follow.
June 2023 all eagerly await the latest product test results and the PR to follow.
So in 4 Junes(and much further back, but I made my point) Hemostyp has gone from Imminent approval, to FDA reset, and incredibly, to testing product for specs validity.
Like the $PPS this PMA is going in the wrong direction.
It reminds me of that movie:
The Curious Case of Benjamin Button.
However, if the goal was 30 months of buying opportunities then well done!
(0)
(0)